Summary
Genzyme Corp (Genzyme), a subsidiary of Sanofi, is a biotechnology company that develops specialty treatments targeting rare and special unmet medical needs. Its product pipeline comprises Dupilumab for atopic dermatitis and asthma; Patisiran for familial amyloid polyneuropathy; Isatuximab for multiple myeloma; and Fitisuran for Hemophilia, among others. The company primarily focuses on rare genetic disorders, kidney diseases, orthopedics, organ transplant, cancer, and immune disease. Genzyme also develops products for the treatment of cardiovascular diseases, neurodegenerative diseases and other areas. It operates a research and development lab and manufacturing plants in the US, Belgium and Ireland. The company has presence in the Americas, Europe, Asia-Pacific, Middle East and Africa. Genzyme is headquartered in Massachusetts, the US.
Genzyme Corp - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Genzyme Corp, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Genzyme Corp, Medical Equipment Deals By Type, 2011 to YTD 2017 6
Genzyme Corp, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Genzyme Corp, Medical Equipment, Deals By Market, 2011 to YTD 2017 8
Genzyme Corp, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Genzyme Corp, Medical Equipment, Deal Details 10
Partnerships 10
Abiogen Pharma Enters Into Licensing Agreement With Genzyme 10
Veracyte Enters into Co-Promotion Agreement with Genzyme 10
Genzyme Extends Co-Promotion Agreement with Veracyte 11
Genzyme Enters Into Co-Marketing Agreement With Veracyte 12
Merger 13
Sanofi Japan and Genzyme Japan Merge 13
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 14
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 15
Equity Offering 16
Alnylam Pharma to Raise USD61.5 Million in Private Placement of Shares 16
Asset Transactions 17
Genzyme Completes Sale Of Its Diagnostic Business To Sekisui Chemical 17
Acquisition 18
Sanofi-Aventis Completes Acquisition Of Genzyme 18
Genzyme Corp - Key Competitors 22
Key Employees 23
Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 28
Product News 28
02/22/2016: Vericel Announces FDA Approval of Epicel HDE Supplement 28
Product Approvals 29
Feb 22, 2016: Vericel Announces FDA Approval of Epicel HDE Supplement 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30
List of Tables
Genzyme Corp, Medical Equipment, Key Facts, 2015 1
Genzyme Corp, Medical Equipment, Deals Summary, 2011 to YTD 2017 1
Genzyme Corp, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Genzyme Corp, Medical Equipment Deals By Type, 2011 to YTD 2017 6
Genzyme Corp, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Genzyme Corp, Deals By Market, 2011 to YTD 2017 8
Genzyme Corp, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Abiogen Pharma Enters Into Licensing Agreement With Genzyme 10
Veracyte Enters into Co-Promotion Agreement with Genzyme 10
Genzyme Extends Co-Promotion Agreement with Veracyte 11
Genzyme Enters Into Co-Marketing Agreement With Veracyte 12
Sanofi Japan and Genzyme Japan Merge 13
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 14
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 15
Alnylam Pharma to Raise USD61.5 Million in Private Placement of Shares 16
Genzyme Completes Sale Of Its Diagnostic Business To Sekisui Chemical 17
Sanofi-Aventis Completes Acquisition Of Genzyme 18
Genzyme Corp, Key Competitors 22
Genzyme Corp, Key Employees 23
Genzyme Corp, Other Locations 24
Genzyme Corp, Subsidiaries 25
List of Figures
Genzyme Corp, Medical Equipment, Deals by Type, 2011 to YTD 2017 1
Genzyme Corp, Medical Equipment, Deals By Year, 2011 to YTD 2017 1
Genzyme Corp, Medical Equipment, Deals By Region, 2011 to YTD 2017 1
Genzyme Corp, Medical Equipment, Deals By Market, 2011 to YTD 2017 1
Genzyme Corp, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Genzyme Corp, Medical Equipment, Deals by Type, 2011 to YTD 2017 6
Genzyme Corp, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Genzyme Corp, Medical Equipment, Deals by Market, 2011 to YTD 2017 8